Tactile Systems Technology Inc - Understand $tcmd stock

$TCMD Market Cap: $456.4 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$285.1M

TTM

Gross Margin

68.46%

TTM

Net Earnings

$15.45M

TTM

Current Assets

$162.4M

Q3 2024

Current Liabilities

$37.15M

Q3 2024

Current Ratio

437.02%

Q3 2024

Total Assets

$287.7M

Q3 2024

Total Liabilities

$79.82M

Q3 2024

Book Value

$207.9M

Q3 2024

Cash

$82.15M

Q3 2024

P/E

29.55

Nov 29, 2024 EST

Free Cash Flow

$39.74M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$274.4M	$246.8M	$208.1M	$187.1M	$189.5M	$143.8M	$109.3M	$84.50M	$62.90M	$47.70M	$37.20M
YoY Change	11.2%	18.61%	11.18%	-1.25%	31.82%	31.54%	29.33%	34.34%	31.87%	28.23%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Revenue	$274.4M	$246.8M	$208.1M	$187.1M	$189.5M	$143.8M	$109.3M	$84.50M	$62.90M	$47.70M	$37.20M
Cost Of Revenue	$79.29M	$70.81M	$59.84M	$54.32M	$55.26M	$41.49M	$29.02M	$42.00M	$30.60M	$22.90M	$18.10M
Gross Profit	$195.1M	$176.0M	$148.2M	$132.8M	$134.2M	$102.3M	$80.27M	$42.50M	$32.20M	$24.80M	$19.10M
Gross Profit Margin	71.11%	71.31%	71.24%	70.97%	70.84%	71.14%	73.45%	50.3%	51.19%	51.99%	51.34%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Selling, General & Admin	$169.2M	$167.2M	$143.6M	$131.0M	$118.4M	$93.98M	$71.31M	$33.80M	$24.50M	$18.20M	$14.30M
YoY Change	1.18%	16.46%	9.62%	10.65%	25.95%	31.79%	110.98%	37.96%	34.62%	27.27%
% of Gross Profit	86.71%	95.02%	96.87%	98.62%	88.18%	91.9%	88.84%	79.53%	76.09%	73.39%	74.87%
Research & Development	$7.823M	$7.088M	$5.659M	$5.264M	$5.174M	$5.289M	$5.060M	$4.500M	$4.300M	$2.800M	$2.400M
YoY Change	10.37%	25.25%	7.5%	1.74%	-2.17%	4.53%	12.44%	4.65%	53.57%	16.67%
% of Gross Profit	4.01%	4.03%	3.82%	3.96%	3.85%	5.17%	6.3%	10.59%	13.35%	11.29%	12.57%
Depreciation & Amortization	$6.539M	$6.268M	$3.681M	$2.794M	$3.538M	$3.737M	$1.800M	$800.0K	$830.0K	$710.0K	$590.0K
YoY Change	4.32%	70.28%	31.75%	-21.03%	-5.33%	107.61%	125.0%	-3.61%	16.9%	20.34%
% of Gross Profit	3.35%	3.56%	2.48%	2.1%	2.64%	3.65%	2.24%	1.88%	2.58%	2.86%	3.09%
Operating Expenses	$177.1M	$188.7M	$150.0M	$136.4M	$123.7M	$99.27M	$76.37M	$38.30M	$28.80M	$21.00M	$16.70M
YoY Change	-6.17%	25.84%	9.92%	10.26%	24.65%	29.98%	99.4%	32.99%	37.14%	25.75%
Operating Profit	$18.04M	-$12.76M	-$1.762M	-$3.628M	$10.50M	$2.990M	$3.898M	$4.200M	$3.400M	$3.800M	$2.400M
YoY Change	-241.41%	624.06%	-51.43%	-134.56%	251.1%	-23.29%	-7.19%	23.53%	-10.53%	58.33%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$2.271M	-$2.715M	-$531.0K	$1.367M	$631.0K	$486.0K	$292.0K	$0.00	-$200.0K	$0.00	$0.00
YoY Change	-16.35%	411.3%	-138.84%	116.64%	29.84%	66.44%		-100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Pretax Income	$15.77M	-$15.47M	-$2.293M	-$2.261M	$11.13M	$3.476M	$4.190M	$4.300M	$3.300M	$3.800M	$2.400M
YoY Change	-201.92%	574.79%	1.42%	-120.32%	220.17%	-17.04%	-2.56%	30.3%	-13.16%	58.33%
Income Tax	-$12.75M	$2.393M	$9.518M	-$1.641M	$158.0K	-$3.147M	-$1.665M	$1.400M	$1.900M	$1.700M	-$800.0K
% Of Pretax Income	-80.82%				1.42%	-90.54%	-39.74%	32.56%	57.58%	44.74%	-33.33%
Net Earnings	$28.52M	-$17.87M	-$11.81M	-$620.0K	$10.97M	$6.623M	$5.855M	$2.900M	$1.400M	$2.100M	$3.200M
YoY Change	-259.6%	51.27%	1805.0%	-105.65%	65.65%	13.12%	101.9%	107.14%	-33.33%	-34.38%
Net Earnings / Revenue	10.39%	-7.24%	-5.68%	-0.33%	5.79%	4.61%	5.36%	3.43%	2.23%	4.4%	8.6%
Basic Earnings Per Share	$1.24	-$0.89	-$0.60	-$0.03	$0.58	$0.36	$0.34
Diluted Earnings Per Share	$1.23	-$0.89	-$0.60	-$0.03	$0.56	$0.34	$0.31	$172.6K	$84.34K	$126.5K	$192.8K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Cash & Short-Term Investments	$75.23M	$38.06M	$40.71M	$58.60M	$53.40M	$45.90M	$43.90M	$41.70M	$7.100M	$5.400M	$6.500M
YoY Change	97.66%	-6.51%	-30.53%	9.74%	16.34%	4.56%	5.28%	487.32%	31.48%	-16.92%
Cash & Equivalents	$61.03M	$21.93M	$28.23M	$47.90M	$22.80M	$20.10M	$24.00M	$30.70M	$7.100M	$5.400M	$6.500M
Short-Term Investments	$14.20M	$16.13M	$12.48M	$10.70M	$30.60M	$25.80M	$19.90M	$11.00M
Other Short-Term Assets	$4.366M	$3.754M	$4.141M	$2.600M	$2.500M	$1.800M	$2.200M	$1.000M	$2.400M	$2.400M	$3.800M
YoY Change	16.3%	-9.35%	59.27%	4.0%	38.89%	-18.18%	120.0%	-58.33%	0.0%	-36.84%
Inventory	$22.53M	$23.12M	$19.22M	$18.60M	$19.10M	$11.20M	$11.00M	$6.600M	$5.800M	$3.500M	$2.900M
Prepaid Expenses
Receivables	$43.17M	$54.83M	$49.48M	$43.80M	$33.40M	$24.30M	$17.60M	$15.00M	$14.20M	$13.70M	$9.600M
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$1.800M	$2.100M	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$145.3M	$119.8M	$113.5M	$123.6M	$108.3M	$85.00M	$76.90M	$64.20M	$29.40M	$25.10M	$22.80M
YoY Change	21.32%	5.47%	-8.13%	14.13%	27.41%	10.53%	19.78%	118.37%	17.13%	10.09%
Property, Plant & Equipment	$25.32M	$27.40M	$30.73M	$27.10M	$23.30M	$4.800M	$3.800M	$1.600M	$1.300M	$1.300M	$1.400M
YoY Change	-7.58%	-10.85%	13.41%	16.31%	385.42%	26.32%	137.5%	23.08%	0.0%	-7.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$22.10M	$3.335M	$1.998M	$12.30M	$10.60M	$10.10M	$2.900M	$2.900M	$1.700M	$1.000M	$1.100M
YoY Change	562.61%	66.92%	-83.76%	16.04%	4.95%	248.28%	0.0%	70.59%	70.0%	-9.09%
Total Long-Term Assets	$136.1M	$135.2M	$130.7M	$50.50M	$43.50M	$22.10M	$11.50M	$9.700M	$7.600M	$6.400M	$6.400M
YoY Change	0.67%	3.45%	158.86%	16.09%	96.83%	92.17%	18.56%	27.63%	18.75%	0.0%
Total Assets	$281.4M	$255.0M	$244.3M	$174.1M	$151.8M	$107.1M	$88.40M	$73.90M	$37.00M	$31.50M	$29.20M
YoY Change
Accounts Payable	$6.659M	$9.984M	$5.023M	$4.200M	$3.800M	$5.100M	$4.300M	$5.000M	$3.300M	$2.500M	$2.000M
YoY Change	-33.3%	98.77%	19.6%	10.53%	-25.49%	18.6%	-14.0%	51.52%	32.0%	25.0%
Accrued Expenses	$25.50M	$28.84M	$19.91M	$18.00M	$16.10M	$10.20M	$9.300M	$7.900M	$4.300M	$2.700M	$3.100M
YoY Change	-11.58%	44.87%	10.59%	11.8%	57.84%	9.68%	17.72%	83.72%	59.26%	-12.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.956M	$2.968M	$2.960M						$0.00	$0.00	$0.00
YoY Change	-0.4%	0.27%
Total Short-Term Liabilities	$41.06M	$64.33M	$34.46M	$26.70M	$21.40M	$16.10M	$14.50M	$13.80M	$9.500M	$6.200M	$5.700M
YoY Change	-36.18%	86.67%	29.07%	24.77%	32.92%	11.03%	5.07%	45.26%	53.23%	8.77%
Long-Term Debt	$26.18M	$45.90M	$51.79M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-42.97%	-11.38%
Other Long-Term Liabilities	$20.56M	$23.37M	$29.76M	$22.60M	$17.70M	$1.700M	$1.100M	$500.0K	$200.0K	$600.0K	$1.400M
YoY Change	-12.01%	-21.47%	31.68%	27.68%	941.18%	54.55%	120.0%	150.0%	-66.67%	-57.14%
Total Long-Term Liabilities	$46.74M	$69.27M	$81.55M	$22.60M	$17.70M	$1.700M	$1.100M	$500.0K	$200.0K	$600.0K	$1.400M
YoY Change	-32.52%	-15.06%	260.84%	27.68%	941.18%	54.55%	120.0%	150.0%	-66.67%	-57.14%
Total Liabilities	$87.80M	$133.6M	$116.0M	$49.30M	$39.20M	$17.80M	$15.70M	$14.30M	$9.700M	$6.800M	$7.000M
YoY Change	-34.28%	15.13%	135.38%	25.77%	120.22%	13.38%	9.79%	47.42%	42.65%	-2.86%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Basic Shares Outstanding	22.93M	20.07M	19.72M	19.35M	18.92M	18.25M	17.36M	8.913M
Diluted Shares Outstanding	23.18M	20.07M	19.72M	19.35M	19.64M	19.35M	18.88M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $456.42 Million

About TACTILE SYSTEMS TECHNOLOGY INC

Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. The company is headquartered in Minneapolis, Minnesota and currently employs 992 full-time employees. The company went IPO on 2016-07-28. The firm's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. The company is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. The company markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The firm markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The firm's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.

Industry: Surgical & Medical Instruments & Apparatus Peers: ABBOTT LABORATORIES Accelerate Diagnostics, Inc ACCURAY INC Apyx Medical Corp CVRx, Inc. Owlet, Inc. RetinalGenix Technologies Inc. Sensus Healthcare, Inc. Stereotaxis, Inc.